• Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001™

    • November 27, 2018
    • Posted By : admin
    • 0 Comment
    •   83 views

    Bioasis Technologies Inc.  (TSX.V:BTI; OTCQB:BIOAF) (the “Company”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB 3 ™   platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced data using the Company’s lead investigational candidate xB 3 -001 in an advanced positron emission tomography and computed tomography (PET/CT) imaging study in non-human primates suggest selective peripheral distribution. The data also indicates penetration of the lymphatic system with xB 3 -001.

    “These findings with xB 3 -001 suggest that the Bioasis platform can enhance the distribution of treatments that have their efficacy limited by inability to penetrate relevant tissue compartments,” said Prof. John H. Krystal, M.D., chairman, Bioasis scientific advisory board (SAB); Robert L. McNeil, Jr., professor of translational research, chair of the department of psychiatry, and professor of neuroscience at the Yale University School of Medicine and chief of psychiatry at Yale-New Haven Hospital.

    In collaboration with Invicro LLC., whole-body distribution of xB 3 -001 was examined in the study using advanced PET/CT imaging in non-human primates. Data from this study suggest a more selective peripheral distribution pattern for xB 3 -001 compared to trastuzumab alone. Importantly, the data also indicate that the xB 3 platform has the potential to penetrate the lymphatic system as shown by the accumulation of xB 3 -001 in the cervical lymph nodes, which is not seen in trastuzumab alone.

    “Together, both the peripheral distribution of xB 3 -001 and penetration of the lymph nodes may indicate additional benefits of xB 3 fusions for patients with neurological and oncological diseases,” said Mark Day, Ph.D., lead investigator of the research; director, president and chief executive officer, Bioasis. “The potential of these findings with the xB 3 platform are truly exciting and we look forward to conducting additional research as it potentially opens significant opportunities for Bioasis.”

  83 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!